Alnylam Pharma (DUL) Q2 2021 Earnings Report

0 Followers

CH:DUL Q2 2021 EPS Results

Actual EPS: -CHF 1.31
Consensus EPS: -CHF 1.31
Beat/Miss: Missed by -CHF 0.00
One Year Ago EPS: -CHF 1.27

CH:DUL Q2 2021 Revenue Results

Actual Revenue: CHF 179.59M
Expected Revenue: CHF 156.38M
Beat/Miss: Beat by +CHF 23.21M
YoY Revenue Growth: +112.15%

Earnings Announcement Details

Quarter: Q2 2021
Date: 08/03/2021
Time: Before Open
Conference Call: Tuesday, August 3, 2021

CH:DUL Upcoming Earnings

Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

Q2 2021 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2021 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2021 Earnings Call Summary

No earnings call summary is available for this earnings event.

CH:DUL Earnings History

CH:DUL earnings history
Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Press Release
Feb 18, 2027	2026 (Q4)	1.40-	0.67	―	―
Oct 29, 2026	2026 (Q3)	1.3512.80	1.5	754.35% (+11.30)
Jul 30, 2026	2026 (Q2)	1.330.99	-0.42	337.25% (+1.40)
Apr 30, 2026	2026 (Q1)	0.711.23	-0.36	443.18% (+1.59)
Feb 12, 2026	2025 (Q4)	0.940.67	-0.53	226.15% (+1.20)
Oct 30, 2025	2025 (Q3)	0.461.50	-0.71	311.49% (+2.21)
Jul 31, 2025	2025 (Q2)	-0.44-0.42	-0.11	-292.31% (-0.31)
May 01, 2025	2025 (Q1)	-0.72-0.36	-0.42	15.38% (+0.07)
Feb 13, 2025	2024 (Q4)	-0.48-0.53	-0.9	40.91% (+0.37)
Oct 31, 2024	2024 (Q3)	-0.75-0.71	0.94	-175.65% (-1.64)
Aug 01, 2024	2024 (Q2)	-0.87-0.11	-1.8	94.12% (+1.69)
May 02, 2024	2024 (Q1)	-0.91-0.42	-1.14	62.86% (+0.72)
Feb 15, 2024	2023 (Q4)	-0.97-0.90	-1.37	34.52% (+0.47)
Nov 02, 2023	2023 (Q3)	-1.180.94	-2.7	134.64% (+3.64)
Aug 03, 2023	2023 (Q2)	-1.23-1.80	-1.86	3.49% (+0.07)
May 04, 2023	2023 (Q1)	-1.36-1.14	-1.63	30.00% (+0.49)
Feb 23, 2023	2022 (Q4)	-1.51-1.37	-1.76	22.22% (+0.39)
Oct 27, 2022	2022 (Q3)	-1.42-2.70	-1.4	-93.02% (-1.30)
Jul 28, 2022	2022 (Q2)	-1.29-1.86	-1.31	-42.24% (-0.55)
Apr 28, 2022	2022 (Q1)	-1.47-1.63	-1.39	-16.96% (-0.24)
Feb 10, 2022	2021 (Q4)	-1.26-1.76	-1.7	-3.35% (-0.06)
Oct 28, 2021	2021 (Q3)	-1.25-1.40	-1.78	21.10% (+0.37)
Aug 03, 2021	2021 (Q2)	-1.31-1.31	-1.27	-3.21% (-0.04)
Apr 29, 2021	2021 (Q1)	―-1.39	-1.32	-5.56% (-0.07)
Feb 11, 2021	2020 (Q4)	―-1.70	-2.01	15.38% (+0.31)
Nov 05, 2020	2020 (Q3)	―-1.78	-1.56	-13.54% (-0.21)
Aug 06, 2020	2020 (Q2)	―-1.27	-1.64	22.77% (+0.37)
May 06, 2020	2020 (Q1)	―-1.32	-1.41	6.36% (+0.09)
Feb 06, 2020	2019 (Q4)	―-2.01	-1.7	-18.18% (-0.31)
Oct 31, 2019	2019 (Q3)	―-1.56	-1.98	20.99% (+0.42)
Aug 06, 2019	2019 (Q2)	―-1.64	-1.33	-23.93% (-0.32)
May 01, 2019	2019 (Q1)	―-1.41	-1.15	-22.70% (-0.26)
Feb 07, 2019	2018 (Q4)	―-1.70	-1.21	-41.22% (-0.50)
Nov 07, 2018	2018 (Q3)	―-1.98	-1.09	-81.34% (-0.89)
Aug 02, 2018	2018 (Q2)	―-1.33	-1.09	-21.64% (-0.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed

Alnylam Pharma earnings date